What diagnostic tests and treatment plan should be used for a patient suspected of West Nile virus infection?

West Nile Virus: Diagnostic Testing and Treatment

For patients with suspected West Nile virus infection presenting with meningitis, encephalitis, acute flaccid paralysis, or unexplained fever in endemic areas, test serum (and CSF if clinically indicated) for WNV-specific IgM antibodies as the primary diagnostic test, and provide supportive care only—no specific antiviral treatment exists.

Diagnostic Testing Algorithm

When to Test

Test any patient presenting with:

• Meningitis
• Encephalitis
• Acute flaccid paralysis
• Unexplained fever during mosquito season (summer/fall) in areas with WNV transmission 1

Primary Diagnostic Test: Serology

IgM antibody testing is the cornerstone of diagnosis 2, 3:

• Serum WNV IgM: First-line test for immunocompetent patients
• CSF WNV IgM: Add when neuroinvasive disease suspected
• Sensitivity >95% when collected ≥4 days after symptom onset 4
• IgM becomes detectable 3-8 days after symptom onset and persists for months

When to Add Molecular Testing (RT-PCR)

RT-PCR should be reserved for specific populations 5, 3:

• Immunocompromised patients (particularly those on anti-CD20 therapies like rituximab, ocrelizumab)
  • IgM sensitivity drops to only 24% in B-cell depleted patients 5
  • RT-PCR sensitivity reaches 93% in this population 5
• Specimens collected ≤3 days after symptom onset (though yield is low) 4
• Solid organ transplant recipients 2

Critical caveat: Routine RT-PCR on all acute serum specimens is not cost-effective—it identifies minimal additional cases beyond IgM testing in immunocompetent patients 4. However, CSF RT-PCR is essential for immunocompromised patients where IgM may be falsely negative 5, 6.

Confirmatory Testing

When IgM is positive, confirmatory plaque reduction neutralization testing (PRNT) is recommended to:

• Rule out cross-reactivity with other flaviviruses (St. Louis encephalitis, dengue, Zika)
• Confirm diagnosis in atypical presentations
• Validate unusual transmission modes 2

Important limitation: Only 25% of laboratories have capacity for confirmatory testing 7, so clinical diagnosis often relies on IgM alone in appropriate epidemiologic context.

CSF Analysis Findings

Typical CSF profile in WNV neuroinvasive disease:

• Elevated opening pressure (often >25 cm H₂O)
• Pleocytosis: 50-500 WBC/µL (can be neutrophil or lymphocyte predominant)
• Elevated protein: 50-150 mg/dL
• Normal glucose 6, 8

Treatment Plan

No Specific Antiviral Therapy Exists

Supportive care is the only evidence-based treatment 1, 2:

• Hospitalization for neuroinvasive disease
• Intensive care monitoring for severe encephalitis or respiratory compromise
• Fluid management and electrolyte correction
• Seizure management if needed
• Respiratory support for acute hypoxemic respiratory failure

Investigational Therapies

Intravenous immunoglobulin (IVIG) is sometimes used off-label:

• Used in 48% of immunocompromised patients in one series 5
• No high-quality evidence supports efficacy
• Consider in severe cases, particularly immunocompromised patients, but recognize this is empiric

Prognosis and Follow-up

Mortality and morbidity are substantial 2, 5:

• Overall mortality: 10% in neuroinvasive disease
• Mortality in age ≥70 years: 20%
• Mortality in immunocompromised (transplant, anti-CD20 therapy, hematologic malignancy): 30-40%
• 75% of immunocompromised patients have worsening disability at 90 days 5
• 30-40% of hospitalized patients discharge to long-term care facilities

• 50% have persistent sequelae: fatigue, weakness, memory loss, depression

Special Populations

Pregnant Women

• Do not screen asymptomatic pregnant women 1
• Test symptomatic pregnant women with serum and CSF IgM
• If positive during pregnancy:
  • Report to health department
  • Consider fetal ultrasound 2-4 weeks after maternal illness onset
  • Test products of conception if miscarriage occurs 1

Immunocompromised Patients

This is a critical diagnostic pitfall 5, 3:

• Anti-CD20 therapies (rituximab, ocrelizumab) dramatically increase risk
• Must order CSF RT-PCR in addition to IgM—IgM alone misses 76% of cases
• Higher ICU admission rates (32%)
• Consider IVIG empirically despite limited evidence

Common Diagnostic Pitfalls

1. Ordering only RT-PCR instead of IgM in immunocompetent patients: This violates guidelines and reduces diagnostic yield 3
2. Failing to test CSF in neuroinvasive presentations: Serum alone may be insufficient
3. Testing too early: IgM sensitivity is poor in first 3 days 4
4. Missing the diagnosis in immunocompromised patients by relying on IgM alone 5
5. Assuming negative CSF PCR rules out WNV: PCR has limited sensitivity outside early viremic window 6

Prevention Counseling

Since no treatment exists, prevention is paramount 2:

• EPA-registered mosquito repellents (DEET, picaridin)
• Protective clothing covering arms and legs
• Avoid outdoor exposure dawn to dusk (peak mosquito feeding)
• Community mosquito control measures